In June 2016, a letter was sent to healthcare professionals about Thalidomide Celgene.
On 20 June 2016, a letter was sent to healthcare professionals about Thalidomide Celgene: risks of viral reactivation and pulmonary hypertension associated with Thalidomide Celgene.
18 July 2016
Medicines and Healthcare products Regulatory Agency
Don’t include personal or financial information like your National Insurance number or credit card details.